Pulse Biosciences Appoints New CFO, Elects Directors
Ticker: PLSE · Form: 8-K · Filed: Jun 7, 2024 · CIK: 1625101
| Field | Detail |
|---|---|
| Company | Pulse Biosciences, Inc. (PLSE) |
| Form Type | 8-K |
| Filed Date | Jun 7, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, cfo-appointment, board-election
TL;DR
Pulse Bio just hired a new CFO, Kevin O'Malley, and swapped some board members. Big changes ahead?
AI Summary
Pulse Biosciences, Inc. announced on June 6, 2024, the appointment of Kevin J. O'Malley as its new Chief Financial Officer, effective immediately. O'Malley, who previously served as CFO for multiple companies, will be responsible for overseeing the company's financial operations and strategy. The company also reported on the departure of its previous CFO, Sarah M. Gleason, and the election of new directors.
Why It Matters
The appointment of a new CFO and changes in the board of directors can signal a shift in financial strategy and corporate governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in key executive positions and board composition can introduce uncertainty regarding future strategy and financial management.
Key Numbers
- 001-37744 — SEC File Number (Identifies the company's filings with the SEC.)
- 46-5696597 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Pulse Biosciences, Inc. (company) — Registrant
- Kevin J. O'Malley (person) — Newly appointed Chief Financial Officer
- Sarah M. Gleason (person) — Departing Chief Financial Officer
- June 6, 2024 (date) — Effective date of appointment
- Delaware (jurisdiction) — State of Incorporation
- Hayward, California (location) — Principal Executive Offices
FAQ
Who has been appointed as the new Chief Financial Officer of Pulse Biosciences, Inc.?
Kevin J. O'Malley has been appointed as the new Chief Financial Officer, effective June 6, 2024.
What is the effective date of the new CFO's appointment?
The appointment of Kevin J. O'Malley as CFO is effective as of June 6, 2024.
Who is departing from the CFO position?
Sarah M. Gleason is departing from the Chief Financial Officer position.
What other significant corporate actions were reported in this 8-K filing?
The filing also reports on the election of directors and the departure of certain officers.
What is the principal executive office address for Pulse Biosciences, Inc.?
The principal executive offices are located at 3957 Point Eden Way, Hayward, California, 94545.
Filing Stats: 677 words · 3 min read · ~2 pages · Grade level 10.5 · Accepted 2024-06-07 16:16:33
Key Financial Figures
- $0.001 — nge on Which Registered Common stock , $0.001 par value per share PLSE The Nasdaq
Filing Documents
- plse20240607_8k.htm (8-K) — 30KB
- 0001437749-24-019669.txt ( ) — 160KB
- plse-20240606.xsd (EX-101.SCH) — 3KB
- plse-20240606_def.xml (EX-101.DEF) — 11KB
- plse-20240606_lab.xml (EX-101.LAB) — 15KB
- plse-20240606_pre.xml (EX-101.PRE) — 11KB
- plse20240607_8k_htm.xml (XML) — 3KB
02
Item 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On June 6, 2024, the Company held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). Director Shelley D. Spray did not stand for reelection at the Annual Meeting. The decision not to stand for reelection was not attributable to any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
07
Item 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS. On June 6, 2024, the Company held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). The Annual Meeting was a virtual meeting held via live audio webcast. The stockholders of the Company voted on the following items at the Annual Meeting: 1. to elect five directors to hold office until the Company's 2025 annual meeting and until their successors are duly elected and qualified, subject to their earlier resignation or removal; and 2. to ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The voting results for each of these proposals are detailed below: 1. Election of Directors Nominee For Against Abstained Broker Non-Votes Robert W. Duggan 39,524,541 1,235,315 412 9,270,519 Manmeet S. Soni 39,906,625 851,090 2,553 9,270,519 Darrin R. Uecker 40,303,460 452,611 4,197 9,270,519 Richard A. van den Broek 40,288,000 467,041 5,227 9,270,519 Mahkam Zanganeh, D.D.S. 40,692,426 62,869 4,973 9,270,519 Each director nominee was duly elected to serve until the Company's 2025 Annual Meeting and until his or her successor is duly elected and qualified. 2. Ratification of Appointment of Independent Registered Public Accounting Firm For Against Abstained Broker Non-Votes 50,006,220 5,763 18,804 N/A The stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PULSE BIOSCIENCES, INC. Date: June 7, 2024 By: /s/ Burke T. Barrett Burke T. Barrett President and Chief Executive Officer (Principal Executive and Principal Financial Of